The ACES Study for Aseptic Pleural Effusion
Active, not recruiting · Not applicable · NCT06210685
Conditions: Pleural Effusion
At a glance
- Research payments reported, 2025
- $97,695
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 25
About the trial
- Sponsor
- Pleural Dynamics, Inc. (with Medical Metrics Diagnostics, Inc)
- Tested
- Automatic Continuous Effusion Shunt implantation (device)
- Dates
- Started 2024-05-12; completion 2025-12
- Results posted
- Not yet
The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires. After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.
From ClinicalTrials.gov, last updated 2025-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Pleural Dynamics Inc. reported $97,695 in research payments for this study in 2025 (9 payments).
Products named: Aces
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mark I. Block, MD Cardiothoracic Surgery · Hollywood, FL
- Jason A. Akulian, M.D. Pulmonology · Baltimore, MD
- Jeffrey P. Thiboutot, M.D. Internal Medicine · Baltimore, MD
- Fabien Maldonado, MD Pulmonology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.